Dare Bioscience

Update in progress

DARE (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Daré Bioscience, Inc. develops therapies for contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. Its portfolio includes XACIATO for bacterial vaginosis; Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream for female arousal; and DARE-HRT1 for menopausal vasomotor symptoms. It also pursues DARE-VVA1, DARE-HPV, and additional vaginal health and fertility programs.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.02; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.26; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive